ERBB2 and breast cancer: Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).